Education
About Us
Working with TipRanks
Follow Us
Satellos Bioscience Inc. (MSCLF)
:MSCLF
Total Valuation
Satellos Bioscience has a market cap or net worth of $79.94M. The enterprise value is $41.10M.
Market Cap$79.94M
Enterprise Value$41.10M
Share Statistics
Satellos Bioscience has 176,305,360 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding176,305,360
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Satellos Bioscience’s return on equity (ROE) is -0.41 and return on invested capital (ROIC) is -40.98%.
Return on Equity (ROE)-0.41
Return on Assets (ROA)-0.38
Return on Invested Capital (ROIC)-40.98%
Return on Capital Employed (ROCE)-0.41
Revenue Per Employee0.00
Profits Per Employee-2.01M
Employee Count14
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Satellos Bioscience is -3.39. Satellos Bioscience’s PEG ratio is ―.
PE Ratio-3.39
PS Ratio0.00
PB Ratio0.49
Price to Fair Value1.40
Price to FCF-4.35
Price to Operating Cash Flow-1.38
PEG Ratio―
Income Statement
In the last 12 months, Satellos Bioscience had revenue of 0.00 and earned -28.10M in profits. Earnings per share was -0.24.
Revenue0.00
Gross Profit-20.00K
Operating Income-27.81M
Pretax Income-28.10M
Net Income-28.10M
EBITDA-28.08M
Earnings Per Share (EPS)-0.24
Cash Flow
In the last 12 months, operating cash flow was -25.21M and capital expenditures -4.00K, giving a free cash flow of -25.21M billion.
Operating Cash Flow-25.21M
Free Cash Flow-25.21M
Free Cash Flow per Share-0.14
Dividends & Yields
Satellos Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.67
52-Week Price Change27.03%
50-Day Moving Average0.45
200-Day Moving Average0.52
Relative Strength Index (RSI)54.08
Average Volume (3m)88.91K
Important Dates
Satellos Bioscience upcoming earnings date is Sep 1, 2025, TBA (Confirmed).
Last Earnings DateMay 13, 2025
Next Earnings DateSep 1, 2025
Ex-Dividend Date―
Financial Position
Satellos Bioscience as a current ratio of 14.16, with Debt / Equity ratio of 0.00%
Current Ratio14.16
Quick Ratio14.16
Debt to Market Cap0.00
Net Debt to EBITDA2.05
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Satellos Bioscience has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Satellos Bioscience EV to EBITDA ratio is -1.34, with an EV/FCF ratio of -1.51.
EV to Sales0.00
EV to EBITDA-1.34
EV to Free Cash Flow-1.51
EV to Operating Cash Flow-1.51
Balance Sheet
Satellos Bioscience has $41.19M in cash and marketable securities with C$0.00 in debt, giving a net cash position of -$41.19M billion.
Cash & Marketable Securities$41.19M
Total DebtC$0.00
Net Cash-$41.19M
Net Cash Per Share-$0.23
Tangible Book Value Per Share$0.59
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Satellos Bioscience is $0.91, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$0.91
Price Target Upside93.62% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―